Severe hypertension development significantly improves progression-free survival in regorafenib treatment for metastatic colorectal cancer.

Saito, Yoshitaka; Takekuma, Yoh; Komatsu, Yoshito; Sugawara, Mitsuru

Saito, Yoshitaka; Takekuma, Yoh; Komatsu, Yoshito; Sugawara, Mitsuru.

Saito Y; Department of Pharmacy, Hokkaido University Hospital, Kita 14-Jo, Nishi 5-Chome, Kita-Ku, Sapporo, 060-8648, Japan.
Takekuma Y; Department of Pharmacy, Hokkaido University Hospital, Kita 14-Jo, Nishi 5-Chome, Kita-Ku, Sapporo, 060-8648, Japan.
Komatsu Y; Cancer Center, Hokkaido University Hospital, Kita 14-Jo, Nishi 5-Chome, Kita-Ku, Sapporo, 060-8648, Japan.
Sugawara M; Department of Pharmacy, Hokkaido University Hospital, Kita 14-Jo, Nishi 5-Chome, Kita-Ku, Sapporo, 060-8648, Japan. msuga@med.hokudai.ac.jp.

Int J Clin Oncol ; 28(9): 1183-1190, 2023 Sep.

Article en En | MEDLINE | ID: mdl-37322220

Asunto(s)

Neoplasias del Colon; Neoplasias Colorrectales; Hipertensión; Neoplasias del Recto; Humanos; Neoplasias Colorrectales/tratamiento farmacológico; Neoplasias Colorrectales/patología; Supervivencia sin Progresión; Estudios Retrospectivos; Neoplasias del Colon/tratamiento farmacológico; Neoplasias del Recto/tratamiento farmacológico; Compuestos de Fenilurea/efectos adversos; Hipertensión/inducido químicamente; Hipertensión/tratamiento farmacológico

Palabras clave

Metastatic colorectal cancer (mCRC); Multikinase inhibitor; Progression-free survival; Regorafenib; Severe hypertension; Vascular endothelial growth factor (VEGF)

Texto completo

Imprimir

XML

PubMed Links

Search on Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Neoplasias del Recto / Neoplasias Colorrectales / Neoplasias del Colon / Hipertensión Tipo de estudio: Observational_studies / Risk_factors_studies Límite: Humans Idioma: En Año: 2023 Tipo del documento: Article

Texto completo

Imprimir

XML

PubMed Links

Search on Google